U0267 Foam

U0267 Foam is a topical emulsion foam formulation under development for the treatment of plaque-type psoriasis. Developed by Stiefel, a GSK Company, this drug is being investigated for its safety and efficacy in clinical trials. While its precise chemical identity is not explicitly stated, its context within clinical trials, particularly its comparison to and co-mention with calcipotriene foam, strongly suggests it is a vitamin D3 analog. Such compounds typically exert their therapeutic effects by modulating keratinocyte proliferation and differentiation, and by influencing immune responses in the skin, thereby helping to normalize skin cell behavior and reduce inflammation associated with psoriasis.